CORT Stock Rises 42% in a Month: Here's What You Should Know

Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.

Zacks Investment Research • Jun 8, 2026

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel (a taxane chemotherapy) in an oral presentation at the ASCO 2026 (Ame.

Business Wire • May 29, 2026

CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up

Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.

Zacks Investment Research • May 28, 2026

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing's syndrome. “Following issuan.

Business Wire • May 27, 2026

Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade

The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • May 19, 2026

Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?

Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.

Zacks Investment Research • May 15, 2026

Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement

Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint.

Seeking Alpha • May 4, 2026

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript

Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 1, 2026

Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk

Corcept Therapeutics Inc. (NASDAQ:CORT) shares are up on Friday as the company reported significant findings from its Phase 2 DAZALS study, demonstrating an 87% reduction in the risk of death for patients with amyotrophic lateral sclerosis (ALS) compared to those receiving a placebo.

Benzinga • May 1, 2026

CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised

Corcept Q1 loss meets estimates, while revenues miss. The company boosts 2026 outlook as new drug Lifyorli and rising Korlym demand reshape growth trajectory.

Zacks Investment Research • May 1, 2026